Faculty, Staff and Student Publications
Publication Date
12-25-2024
Journal
The Journal for ImmunoTherapy of Cancer
DOI
10.1136/jitc-2024-008950
PMID
39721752
PMCID
PMC11683914
PubMedCentral® Posted Date
12-25-2024
PubMedCentral® Full Text Version
Post-print
Abstract
INTRODUCTION: Despite significant successes, immune checkpoint blockade fails to achieve clinical responses in a significant proportion of patients, predictive markers for responses are imperfect and immune-related adverse events (irAEs) are unpredictable. We used T-cell receptor (TCR) sequencing to systematically analyze prospectively collected patient blood samples from a randomized clinical trial of dual immune checkpoint inhibitor therapy to evaluate changes in the T-cell repertoire and their association with response and irAEs.
METHODS: Patients with immunotherapy-naïve metastatic non-small cell lung cancer (NSCLC) were treated with ipilimumab and nivolumab according to trial protocol (LONESTAR, NCT03391869). Blood samples were systematically obtained at baseline (n=107), after 12 weeks of ipilimumab and nivolumab (n=91), and at the time of grade ≥2 irAEs (n=77). For analysis of T-cell repertoire, we performed immunoSEQ to assess the complementary determining region 3β region of the TCR involved in antigen binding.
RESULTS: A total of 250 samples from 119 patients were analyzed. Patients who had a response to therapy exhibited greater T-cell diversity at baseline. Interestingly, patients with irAEs demonstrated lower T-cell richness at the time of toxicity compared with those without irAEs.
CONCLUSION: Our study highlights the potential impact of peripheral blood T-cell repertoire on clinical response and toxicities from the combination of ipilimumab and nivolumab in patients with metastatic NSCLC. These findings suggest that analysis of peripheral blood T-cell repertoire may help to guide patient selection for treatment with ipilimumab and nivolumab.
TRIAL REGISTRATION NUMBER: NCT03391869.
Keywords
Adult, Aged, Female, Humans, Male, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Ipilimumab, Lung Neoplasms, Neoplasm Metastasis, Nivolumab, T-Lymphocytes
Published Open-Access
yes
Recommended Citation
Altan, Mehmet; Li, Ruoxing; Li, Ziyi; et al., "High Peripheral T Cell Diversity Is Associated With Lower Risk of Toxicity and Superior Response to Dual Immune Checkpoint Inhibitor Therapy in Patients With Metastatic NSCLC" (2024). Faculty, Staff and Student Publications. 3322.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/3322
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons